pyrroles has been researched along with Leukemia, Megakaryocytic in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Amboldi, N; Avanzi, N; Bertrand, J; Bindi, S; Brasca, MG; Canevari, G; Casero, D; Ciomei, M; Colombo, N; Cribioli, S; Donati, D; Fachin, G; Felder, ER; Galvani, A; Gnocchi, P; Isacchi, A; Motto, I; Nesi, M; Panzeri, A | 1 |
Ikezoe, T; Koeffler, HP; Komatsu, N; Nishioka, C; Takeshita, A; Taniguchi, A; Togitani, K; Yang, J; Yokoyama, A | 1 |
2 other study(ies) available for pyrroles and Leukemia, Megakaryocytic
Article | Year |
---|---|
Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.
Topics: Amides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression; High-Throughput Screening Assays; Humans; Janus Kinase 2; Leukemia, Megakaryoblastic, Acute; Megakaryocyte Progenitor Cells; Mice; Mice, Nude; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Kinase Inhibitors; Pyrroles; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2015 |
Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; MAP Kinase Kinase 1; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Pyrroles; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sunitinib; Tumor Cells, Cultured | 2008 |